Anna M.D. Watson - Concepedia

Author

Anna M.D. Watson

Baker Heart and Diabetes Institute ORCID

Also Known As

A M Watson, A Watson, A. M. D. Watson, A. M. Watson, A.M.D. Watson, AMD Watson, Anna M D Watson, Anna M. D. Watson, Anna M.D. Watson, Anna Margareta Dorothea Watson

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Baker Heart and Diabetes Institute Monash University The University of Melbourne Florey Institute of Neuroscience and Mental Health The Alfred Hospital

About

Anna M.D. Watson is an author at Baker Heart and Diabetes Institute specializing in medicine, physiology, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	1.2K
2	Health Sciences	9	9	833
3	Public Health	3	3	169
4	Social Sciences	2	2	37
5	Anesthesia	1	1	70

Anna M.D. Watson

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes Aino Soro‐Paavonen, Anna M.D. Watson, Jiaze Li, Diabetes	2008	401
miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 Expression Bo Wang, Philip Koh, Catherine E. Winbanks, Diabetes	2010	353
The neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat Brian J. Oldfield, Michelle Giles, Anna M.D. Watson, Neuroscience Hypothalamic CircuitsNeurochemical CharacterisationNeuroendocrine MechanismHypothalamic PeptideHypothalamic Pathways	2002	316
E-Cadherin Expression Is Regulated by miR-192/215 by a Mechanism That Is Independent of the Profibrotic Effects of Transforming Growth Factor-β Bo Wang, Michal Herman‐Edelstein, Philip Koh, Diabetes	2010	245
Leptin-Induced Nuclear Translocation of STAT3 Immunoreactivity in Hypothalamic Nuclei Involved in Body Weight Regulation Thomas Hübschle, Elke Thom, Anna M.D. Watson, Journal of Neuroscience Human GrowthNeuroendocrinologyStat3 ImmunoreactivityAdipokinesGastrointestinal Peptide Hormone	2001	194
Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions Anna M.D. Watson, Gavin Lambert, Kathryn J. Smith, Hypertension Heart FailureSmall PeptideCardiovascular FunctionActh ReleaseAdrenal Gland	2003	88
A Novel Interaction Between Sympathetic Overactivity and Aberrant Regulation of Renin by miR-181a in BPH/2J Genetically Hypertensive Mice Kristy L. Jackson, Francine Z. Marques, Anna M.D. Watson, Hypertension	2013	81
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice Anna M.D. Watson, J. Li, Christoph Schumacher, Diabetologia InflammationMetabolic SyndromeVascular DiseaseMedicineDiabetes	2009	79
Increased cardiac sympathetic nerve activity in heart failure is not due to desensitization of the arterial baroreflex Anna M.D. Watson, Sally G. Hood, Rohit Ramchandra, American Journal of Physiology-Heart and Circulatory Physiology HypertensionHeart FailureCardiovascular FunctionPeripheral Nervous SystemDiastolic Function	2007	70
Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice Anna M.D. Watson, Aino Soro‐Paavonen, Karen Sheehy, Diabetologia Metabolic SyndromeAgingCardiovascular DiseaseLongevityMedicine	2010	70

Page 1